Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study

[1]  M. Koopmans,et al.  Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming , 2022, The New England journal of medicine.

[2]  N. Andrews,et al.  Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England , 2022, Nature Medicine.

[3]  N. Andrews,et al.  Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines , 2022, The New England journal of medicine.

[4]  G. Screaton,et al.  Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.

[5]  B. Alarcón,et al.  Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination , 2021, PLoS pathogens.

[6]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[7]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[8]  Michael I. Mandel,et al.  Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.

[9]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[10]  A. Nordström,et al.  Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study , 2021, The Lancet Regional Health - Europe.

[11]  O. A. Ogun,et al.  Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study , 2021, The Lancet.

[12]  P. Klenerman,et al.  Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses , 2021 .

[13]  A. Singh,et al.  Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study , 2021, Vaccine.

[14]  S. Bhatt,et al.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion , 2021, Nature.

[15]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[16]  Gareth Iacobucci.  Covid-19: Protection from two doses of vaccine wanes within six months, data suggest , 2021, BMJ.

[17]  V. Libri,et al.  Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.

[18]  M. Snape,et al.  Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data , 2021, The Lancet.

[19]  P. Bhardwaj,et al.  Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review , 2021, Indian Journal of Clinical Biochemistry.

[20]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[21]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.